Lead the clinical development team, including operations, medical, biostatistics and medical for Ph1 to Ph3 studies

o Lead direct development and creation of clinical development plans and strategists across respiratory and life cycle indicationso Direct successful progression of treatments to Phase III clinical trials

o Led Respiratory function team consisting of four physicians and scientistso Ensured alignment of clinical development plans with target product profiles and incorporate endpoints necessary for reimbursement, present at payer ad boards and discuss reimbursement planso Executed clinical studies by closely liaising with CROs, vendors and marketing companies to ensure delivery ahead of planned timingso Organised multiple advisory boards with key experts, build external collaborations to ensure peer review, shaping of science strategies and serve as point of contact for Investigator Initiated Studieso Mentored employees globally cross-functionally within MedImmune

o Directed early phase programme for a novel small molecule targeted at multiple sclerosiso Led a Phase 1/Phase 2 clinical programme of an anti-CD3 monoclonal antibody in auto-immune diseases including rheumatoid arthritis, myasthenia gravis, inflammatory bowel disease and psoriasiso Provided medical governance for all Experimental Biomedicine Immuno-inflammation CEDD projects, together with input for respiratory compounds including cystic fibrosis, asthma and COPD.

o Authored key documents and integrated summary of safety as part of a successful regulatory submission to FDA (Supplemental filing) and Europe for ropinirole XL in Parkinson’s diseaseo Responsible for writing key documents and integrated summary of safety, contributing to a successful regulatory submission to FDA for ropinirole CR-RLS in Restless Leg Syndromeo Managed clinical pharmacology data at regulatory interactions, including FDA and EMA, for ropinirole CR-RLS in Restless Leg Syndromeo Led early development programme for novel small molecules targeted at Alzheimer’s disease and multiple sclerosiso Authored responses to regulatory agencies, clinical pharmacology sections of the label, 120-day safety updates and final safety updates for both filings and all annual safety updates

o Directed a team of four physicians as Lead Principal Investigator at LCG Bioscienceo Successfully conducted approximately 20-30 Phase 1/Phase 2a studies per year for Serono and a wide range of major pharmaceutical sponsors and smaller companieso Advised companies on the design of clinical trials, clinical development programmes, pre-clinical to clinical translation of toxicology, toxicokinetic and safety pharmacology data for small and large novel compounds